• Agarwal, Rajesh, Ph.D.
• Anchordoquy, Thomas J., Ph.D.
• Anderson, Peter, Pharm.D.
• Aquilante, Christina, Pharm.D.
• Bain, David L., Ph.D.
• Carpenter, John, Ph.D.
• Franklin, Christopher, Ph.D.
• Hail, Jr., Numsen, Ph.D.
• Irons, Richard D., Ph.D.
• Jones Braun, LaToya, Ph.D.
• Ju, Cynthia, Ph.D.
• Kiser, Jennifer, Pharm.D.
• Kompella Uday B., PhD
• Malkinson, Alvin M., Ph.D.
• Mallela, Krishna M. G., Ph.D.
• Maluf, N. Karl, Ph.D.
• Patel, Manisha, Ph.D.
• Petersen, Dennis R., Ph.D.
• Radcliffe, Richard, Ph.D.
• Ross, David, Ph.D.
• Ruth, James. A., Ph.D.
• Scheinman, Robert I., Ph.D.
• Thompson, John A., Ph.D.
• Vasiliou, Vasilis, Ph.D.

Christina Aquilante, Pharm.D.

Assistant Professor, Department of Pharmaceutical Sciences

Mailing address:
4200 E. 9th Ave, C238
Denver, CO 80262

Telephone:
Voice:     303-315-3119
Lab:        303-315-3120
E-Mail:   Christina.Aquilante@uchsc.edu

Training and Education:
Pharm.D., University of North Carolina at Chapel Hill
Pharmacy Practice Residency, Shands Hospital at the University of Florida
Post-Pharm.D. Research Fellowship in Cardiovascular Pharmacogenomics, University of Florida College of Pharmacy

Research Interest:
The primary aim of my patient-oriented clinical pharmacogenomic research program is to determine if polymorphisms influence interindividual variability in the pharmacokinetics, pharmacodynamics, and drug interactions of commonly used drugs in diabetes and cardiovascular disease.  Our current focus is on agents in the thiazolidinedione drug class.  Thiazolidinediones are insulin sensitizing drugs that are used to treat type 2 diabetes.  Our current studies are examining whether polymorphisms in drug metabolizing enzyme and drug transporter genes influence thiazolidinedione disposition, response, and drug interactions in healthy volunteers and in patients with type 2 diabetes.  In addition to lowering blood glucose, thiazolidinediones also possess beneficial pleiotropic effects.  As such, the secondary aim of my research program is to investigate the cytokine-modulating and insulin-sensitizing effects of thiazolidinediones in non-diabetic patients at high risk for the future development of diabetes and cardiovascular disease.  In addition, we are studying whether polymorphisms influence interindividual variability in baseline cytokine levels and disease risk in this non-diabetic population. 

Teaching:
Professional Program:
PHRD 3560 Principles of Drug Action
PHRD 4600 Clinical Science Foundations
PHRD 5650 Comprehensive Patient Care
PHRD 5700 Integrated Organ Systems IX
Graduate Program:
TXCL 7561 Drug Metabolism and Pharmacogenetics

Representative Publications:
Aquilante CL, Langaee TY, Anderson PL, Zineh I, Fletcher CV.  Multiplex PCR-Pyrosequencing Assay for Genotyping CYP3A5 Polymorphisms.  Clin Chim Acta; 2006 May 13 [Epub ahead of print].
Aquilante CL, Langaee TY, Yarandi HN, Tromberg JS, Mohuczy D, Gaston KL, Waddell CD, Chirico MJ, Johnson JA.  Influence of coagulation factor, vitamin K epoxide reductase complex subunit 1, and cytochrome P450 2C9 gene polymorphisms on warfarin dose requirements.  Clin Pharmacol Ther;  2006; 79:291-302.
Aquilante CL, Zineh I, Beitelshees AL, Langaee TY.  Primer of Common Laboratory Methods in Pharmacogenomics.  Am J Health Syst Pharm; 2006 in press.
Zineh I, Aquilante CL, Langaee TY, Beitelshees AL, Arant CB, Wessel TR, Schofield RS.  Association of CXCL5 gene polymorphisms with plasma and leukocyte-produced epithelial neutrophil-activating peptide (ENA-78) concentrations.  Cytokine.  2006; 33:258-63.
Lin M, Aquilante CL, Johnson JA, Wu R.  Sequencing drug response with HapMap.  Pharmacogenomics J.  2005;5:149-56.

Recent Publications

Last updated: 6/25/07